A team of researchers from the Department of Clinical and Experimental Medicine at the University of Catania, Italy recently reviewed the co-occurrence of additional diseases in Idiopathic Pulmonary Fibrosis and their current therapeutic strategies. The study, entitled “IPF, comorbidities and management implications,“ was published in the Sarcoidosis Vasculitis…
Idiopathic Pulmonary Fibrosis Comorbidities Discussed By Researchers
In a new study, researchers demonstrated the protective effects of vitamin D in a mouse model of pulmonary fibrosis induced by the chemotherapeutic drug bleomycin. The research paper, entitled “Preventive effects of vitamin D treatment on bleomycin-induced pulmonary fibrosis,” was published in the Nature journal Scientific Reports. Vitamin…
Findings by a team of researchers suggest that levels of circulating endothelial cells and fibrocytes may be used as predictive biomarkers in idiopathic pulmonary fibrosis (IPF). The team’s study, “Levels of circulating endothelial cells are low in idiopathic pulmonary fibrosis and are further reduced by anti-fibrotic treatments,” was published in…
Asha is a young woman who has the daily challenge of living with Lupus and Pulmonary Fibrosis. Watch this video of her talking about her own story and how it is to live with these diseases. Learn more about Pulmonary Fibrosis: https://bit.ly/1lfMsiZ and Lupus: https://bit.ly/1TXhzeU…
https://www.youtube.com/watch?v=zKQg8dyKafM Learn about Pulmonary Fibrosis, its causes and clinical trials being planned. Learn more about Pulmonary Fibrosis: https://bit.ly/1lfMsiZ…
The University of Virginia Health System (UVA) recently joined the Pulmonary Fibrosis Foundation (PFF)’s Care Center Network, making it one of 19 new facilities chosen after careful peer review for inclusion in this signature PFF program. The PFF Care Center Network now comprises 40 medical centers with expertise in the…
Afferent Pharmaceuticals, a biotechnology company dedicated to therapies for neurogenic disorders, recently announced the beginning of a Phase 2 clinical trial to assess its candidate product AF-219 for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF). Neurogenic disorders are conditions associated with the…
In a recent study in the journal Scientific Reports, a team of researchers demonstrated the use of a new imaging modality that might detect and monitor fibrosis in the lungs of patients with pulmonary disorders and reduce the number of animals required for pulmonary research studies. The cause…
Read the articles: 1. Potential Therapy for Severe Lung Disease Advances at aTyr Pharma 2. IPF Experts Discuss Disease Diagnosis and Treatment at CHEST 2015 3. Potential IPF Disease Biomarkers Seen in Patients’ Blood …
Emphysema is a type of lung disease that causes shortness of breath. In a person with emphysema, the alveoli are damaged. The alveoli walls and the elastic fibers are damaged and lost. Learn more about Emphysema and Pulmonary Fibrosis: https://bit.ly/1ONmRdG…
